Navigation Links
RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
Date:12/4/2013

n the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contacts

RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com


'/>"/>
SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014  RESMED INC. (NYSE: ... quarter of fiscal year 2015 results on Thursday, January 22, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS Asserts its Position in Difficult Environment 2
... to Initiate Phase 2b in Second Quarter of 2008 ... - Conference Call Tomorrow at 8:00 a.m. Eastern Time ... Inc.,(Nasdaq: RDEA ) today announced positive preliminary results ... novel,investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in,patients with human ...
... to Develop Disease Treatments for Diabetic Kidney Disease and ... Retinopathy, Each Multi-Billion-Dollar Drug Markets, JENKINTOWN, Pa., March ... new class of compounds that inhibit the,production of RAGE, ... that a RAGE inhibitor would be an important,addition to ...
Cached Medicine Technology:Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 2Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 4Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor 2
(Date:12/19/2014)... Pain Free Living a leader in ... a new Superior magnetic necklace using ion ... strongest neodymium magnets for the fastest pain relief in ... Superior Magnetics brand for the fastest relief by using ... therapy using Superior Magnetic Jewelry at fairs and festivals” ...
(Date:12/19/2014)... From November 24, 2014, Siddhi Yoga ... year 2014 in its Goa retreat . This is ... Indian winters, from November to March, Siddhi Yoga will organize ... Arambol, Goa. The Goa training sessions will conclude in March ... teacher training, the 10th intake is also a 200 ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 After a ... performer is again returning to the stage to entertain ... husband for concert performances, and the successful tour has ... originally announced. , Visit Ticketability.com for ... newly-announced Detroit shows at fair prices. , Music fans ...
(Date:12/19/2014)... Texas (PRWEB) December 19, 2014 ... exhibited at the AMSUS Society for Federal Health ... the locum tenens industry to military and federal ... attended the National Veterans Small Business Engagement (NVSBE) ... Tenens continues to be a vital solution in ...
(Date:12/19/2014)... Being in good shape seems to reduce your risk of ... from more than 57,000 Americans, including more than 35,000 with ... 2009. Those in the poorest shape had a more ... the start of the study, compared to a 50 percent ... the more than 8,000 people diagnosed with high blood pressure ...
Breaking Medicine News(10 mins):Health News:New Superior Magnetic Necklace Relieves Migraine Headache 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 3Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2Health News:Being Fit Keeps Blood Pressure in Check 2
... to new research reported in the journal ... Shirota may ease symptoms of anxiety in people ... with CFS received daily supplements of either Lactobacillus ... Compared to the placebo group, those receiving ...
... loved one suffers a stroke, you,ll probably be left ... side effects should you watch for? Does your ... of the stroke survivor?To help answer common questions, the ... tips to help family members cope with their new ...
... soaks, twice a week, prevent painful flare-ups, study finds ... baths offer a safe, simple and inexpensive way of ... The skin disease, which affects 17 percent of school-age ... to concentrate in school. , Eczema-related itching can ...
... may now register to attend TCT 2009 (Transcatheter ... Cardiovascular Research Foundation. TCT gathers leading medical researchers ... and discuss the latest developments in the field ... its 21st year, TCT brings state-of-the-art techniques and ...
... Hospital,s Bluhm Cardiovascular Institute is the first ... country to implant a new experimental left ventricular assist ... condition where the heart cannot pump enough blood to ... System) features the HVAD Pump, the smallest ...
... fan technology teams up with ultraviolet-C light energy for ... the introduction of the Healthy Fan, which improves the ... 99 percent of airborne germs. The Healthy Fan maximizes ... combination with a mounted air purifying medallion. It ...
Cached Medicine News:Health News:New Study Shows Supplementing With Probiotics May Ease Anxiety 2Health News:American Stroke Association Provides Tips for Caregivers as Part of Stroke Month in May 2Health News:American Stroke Association Provides Tips for Caregivers as Part of Stroke Month in May 3Health News:Diluted Bleach Baths Ease Kids' Eczema 2Health News:Media registration now open for TCT 2009 2Health News:Smallest full support heart assist device on trial at Northwestern Memorial 2Health News:Haledyne Debuts Air Sanitizing Technology for Healthier Home 2Health News:Haledyne Debuts Air Sanitizing Technology for Healthier Home 3
... for Cardiology is the first digital solution ... modalities both within and outside cardiology. From ... the archival solutions, Agfas combined expertise in ... and their customers to work the way ...
Full Digital Ultrasound System...
... the latest technologies to help expand your ... These advancements increase system utility and provide ... visualization of even the smallest details. And ... information delivery and expedite a higher quality ...
This catheter is intended for ultrasound examination of coronary intravascular pathology ONLY. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal coronary i...
Medicine Products: